Imagabalin
 | |
| Systematic (IUPAC) name | |
|---|---|
| (3S,5R)-3-amino-5-methyloctanoic acid | |
| Clinical data | |
| Identifiers | |
|
610300-07-7 610300-00-0 (hydrochloride) | |
| None | |
| PubChem | CID 10236037 |
| ChemSpider | 8411525 |
| Synonyms | PD-0332334; PD-332,334 |
| Chemical data | |
| Formula | C9H19NO2 |
| 173.253 g/mol | |
|
SMILES
| |
| |
Imagabalin (INN, USAN; PD-332,334) is a drug which acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] Under development by Pfizer as a pharmaceutical medication, it has demonstrated preclinical efficacy of anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity and is currently in phase III clinical trials for the treatment of generalized anxiety disorder.[2][3]
See also
References
- ↑ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (July 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology". Brain Research 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMID 21664606.
- ↑ 2.0 2.1 Larry Ereshefsky (2008). "Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models" (PDF) (Press release). p. 11. Retrieved 2012-04-22.
- ↑ "A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder". Retrieved 2012-04-22.
| ||||||||||||||||||||||||||||||||||||||||||||||||